Open | $35.400 |
Close | $34.065 |
Volume / Avg. | 930.519K / 1.481M |
Day Range | 34.030 - 35.720 |
52 Wk Range | 16.950 - 49.500 |
Market Cap | $2.801B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 48 |
Short Interest | 20.85% |
Days to Cover | 9.09 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), MoonLake (NASDAQ:MLTX), SpringWorks Therapeutics (NASDAQ:SWTX), TG Therapeutics (NASDAQ:TGTX) and Arrowhead Pharma (NASDAQ:ARWR).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Barclays on Wednesday, February 28, 2024. The analyst firm set a price target for 42.00 expecting BEAM to rise to within 12 months (a possible 22.45% upside). 15 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $34.3 last updated March 18, 2024 at 5:48 PM EDT.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.